CD38 and chronic myelogenous leukemia, BCR-ABL1 positive: However, as CD38 is expressed in normal stem cells, targeting CD38 has serious side effects, so CD38 CAR may be an option for therapy for myeloid CML-BP patients who could be eligible for BM transplant [26].